Fortrea Holdings Inc (FTRE) Stock AnalysisFTREStock AnalysisFortrea Holdings Inc

Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

Fortrea Holdings Inc is a good buy right now, trading at $18.81 with a forward P/E of 13.18, which suggests potential for growth compared to its current valuation. The recent earnings report showed a non-GAAP EPS of $0.23, beating expectations by $0.05, indicating improved profitability. However, a risk is the insider selling activity, which has increased by 267.54% over the last month, suggesting potential concerns among insiders.